ホーム>>Signaling Pathways>> PROTAC>>dTRIM24

dTRIM24

カタログ番号GC35904

dTRIM24 は、PROTAC に基づく TRIM24 の選択的二機能分解剤であり、von Hippel-Lindau および TRIM24 のリガンドで構成されています。

Products are for research use only. Not for human use. We do not sell to patients.

dTRIM24 化学構造

Cas No.: 2170695-14-2

サイズ 価格 在庫数 個数
10mM (in 1mL DMSO)
$624.00
在庫あり
5mg
$324.00
在庫あり
10mg
$510.00
在庫あり
25mg
$2,271.00
在庫あり
50mg
$2,271.00
在庫あり
100mg
$3,893.00
在庫あり

Tel:(909) 407-4943 Email: sales@glpbio.com

顧客レビュー

カスタマーレビューに基づきます。

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Protocol Chemical Properties Product Documents Related Products

dTRIM24 is a selective bifunctional degrader of TRIM24 based on PROTAC. TRIM24[2].

dTRIM24 is a degrader of TRIM24 bromodomain. Recruitment of the VHL E3 ubiquitin ligase by dTRIM24 elicits potent and selective degradation of TRIM24. The anti-proliferative consequences of chemical degradation versus inhibition of TRIM24 are assessed. Growth over time is determined for MOLM-13 cells treated with dTRIM24, IACS-9571, VL-269, and eTRIM24. dTRIM24 suppresses growth to a greater extent than does IACS-9571, accompanied by apoptosis measured as enhanced PARP cleavage. In agreement with a sustained proliferative defect observed following dTRIM24 treatment, near-complete degradation of TRIM24 is observed in dTRIM24-treated cells throughout the duration of the experiment[2].

[1]. Gechijian LN, et al. Functional TRIM24 degrader via conjugation of ineffectual bromodomain and VHL ligands. Nat Chem Biol. 2018 Apr;14(4):405-412.

レビュー

Review for dTRIM24

Average Rating: 5 ★★★★★ (Based on Reviews and 6 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for dTRIM24

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.